Alligator Bioscience, a clinical-stage biotechnology company, has appointed Julie Silber as the new senior director of communications and investor relations.
She joins Alligator Bioscience with more than 20 years of IR, strategic communications and executive financial leadership experience.
Over the last several years, Silber’s main focus has been working with life sciences companies in the Nordics, most recently as senior director of IR at Immunovia, a diagnostic company. She also served as interim chief financial officer/IR director at Dicot, a bio-pharmaceutical company.
‘We are excited to welcome an executive of Julie’s caliber and experience to help strengthen and expand Alligator’s communications and investor relations program. She will be working closely with Alligator’s senior management on the exciting prospects of expanding our reach and exposure with the investment community,’ says Søren Bregenholt, CEO of Alligator Bioscience.
‘We are at a pivotal time in the development of the company and Alligator’s strategic communications plan and IR function need to be able to support the strategic plan for the years to come.’
